Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4 Puritas >98.0% (HPLC) Lenvatinib Mesylate intermedia Factory
Ruifu Chemical Supple Lenvatinib Mesylate media cum puritate
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1-(2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylatus CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene)-2,2-Dimethyl-1,3-Dioxane-4,6-Dione CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus CAS 205448-66-4
Nomen chemicum | Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus |
Synonyma | Lenvatinib immunditia 47;4-Chloro-7-Methoxyquinoline-6-Carboxylic Acidum Methyl Ester;4-Chloro-7-Methoxy-6-Quinolinecarboxylic Acidum Methyl Ester;Lenvaint-D |
CAS Number | 205448-66-4 |
CATTUS Number | RF-PI1970 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C12H10ClNO3 |
M. Pondus | 251.67 |
Ferveret | 377.4±37.0℃ |
Density | 1.320±0.06 g/cm3 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Off-White ad Yellow solidus pulveris |
1 H NMR Spectrum | Congruunt cum Structure |
Puritas / Analysis Methodus | >98.0% (HPLC) |
Damnum in Siccatio | <1.00% |
Totalis immunditias | <2.00% |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedia/Immunditia de Mesylate Lenvatinib (CAS: 857890-39-2) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylatus (CAS: 205448-66-4) medius est Mesylate Lenvatinib (CAS: 857890-39-2).Lenvatinib est medicamentum thyreoidum ab Eisai Corporatione Iaponiae (Codex: E7080) inhibitoris multi-receptoris tyrosini kinasi oralis pertinens et kinasum activitatem endothelialem factorem receptorum R1 (FLT1) inhibere potest; VEG-FR2 (KDR), R3 (FLT4).Lenvatinib etiam impedire potest implicationem aliorum RTKs in angiogenesi pathologica, tumore augmento, et progressu cancri, exceptis functionibus normalibus cellularum inclusis fibroblast aucti (FGF) receptores FGFR1, II, III, IV;factor augmentationis receptae (PDGFR [alpha]), KIT, RET.[Indicationes]: Lenvatinib apta est curatione aegrorum cancri thyroideae localis recursu vel metastasi speciei, progressionis generis et iodi-refractionis radioactivi speciei differentiatae.